新型冠状病毒疫苗激发<b>T</b>淋巴细胞免疫作用的优势探讨

卓家同

doi:10.19428/j.cnki.sjpm.2024.23382

新型冠状病毒疫苗激发T淋巴细胞免疫作用的优势探讨

卓家同

Advantages of COVID-19 vaccine in the T cell immune response

ZHUO Jiatong

摘要

摘要:
目的探讨新型冠状病毒疫苗（简称“新冠疫苗”）激发T淋巴细胞的免疫作用的优势。
方法通过分析新型冠状病毒（简称“新冠病毒”）原始株、德尔塔变异株和奥密克戎变异株不同时段潜伏期百分构成与mRNA新冠疫苗、新冠灭活疫苗相应预防感染及发病效果，论证T细胞免疫与B细胞免疫激发时程和相关实验。
结果 mRNA新冠疫苗预防感染及发病与新冠病毒潜伏期≥5 d百分构成一致，新冠灭活疫苗预防感染及发病与新冠病毒潜伏期≥8 d百分构成一致，mRNA新冠疫苗预防新冠病毒引起的早期感染及发病更有效。
结论 mRNA新冠疫苗细胞内激发T细胞免疫比新冠灭活疫苗细胞外激发B细胞免疫更快。

Abstract:
Objective To illustrate the mechanism of COVID-19 vaccine in the T cell immune response.
Methods Based on the characteristics of T cell and B cell immune response， we matched the data of incubation periods across the SARS-CoV-2 prototype strain， Delta variants， and Omicron variants and effectiveness of mRNA and inactivated COVID-19 vaccines for analysis.
Results The effectiveness of mRNA COVID-19 vaccine against infection and onset was consistent with incubation period principally being ≥5 days. In contrast， the effectiveness of inactivated COVID-19 vaccine was consistent with incubation period principally being ≥8 days.
Conclusion It may be interpreted by faster T cell immune response stimulated by mRNA vaccine， compared to B cell immune response by inactivated vaccine.

HTML全文

参考文献(30)

施引文献

资源附件(0)